In this article by The Medicine Maker, Dr. Andrew Lewis, the Chief Scientific Officer at Quotient Sciences and other experts discuss the potential of technology in shortening drug development timelines and enhancing productivity.
The discussion highlights the optimism around AI's potential to revolutionize pharma over the next decade and improve clinical trial processes.
Continue reading the full article on The Medicine Maker